Get started
Author

Sandra Sackmann

Observed names: S Sackmann, S. Sackmann
OpenAlex ID: A5018391059
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer
2018 · Jan A. Stratmann, Sebastian Michels, et al. · Journal of Cancer Research and Clinical Oncology · 11
P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts
2018 · J. Roeper, M. Falk, et al. · Journal of Thoracic Oncology · 10
PDF
Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts.
2018 · Julia Roeper, Markus Falk, et al. · Journal of Clinical Oncology · 10
Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network
2017 · J. Roeper, A. Lueers, et al. · Annals of Oncology · 5
PDF
Klinik und Diagnostik des malignen Pleuramesothelioms
2009 · S. Sackmann · Der Pneumologe · 5
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)
2023 · Frank Griesinger, Wilfried E.E. Eberhardt, et al. · JTO Clinical and Research Reports · 4
PDF
Impact on OS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients: Results of the NOWEL network.
2017 · Julia Roeper, Maria Netchaeva, et al. · Journal of Clinical Oncology · 3
Obere Einflussstauung
2006 · S. Sackmann · Der Pneumologe · 3
1244P Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP)
2020 · M. Faehling, C. Schumann, et al. · Annals of Oncology · 2
PDF
Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients
2019 · J. Roeper, A.C. Lueers, et al. · Annals of Oncology · 2
1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery
2020 · R. Shah, L.V. Klotz, et al. · Annals of Oncology · 1
PDF
Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network
2019 · J. Roeper, M. Falk, et al. · Annals of Oncology · 1
Risk of not receiving 2nd line therapy is high in EGFR mt+ patients: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients
2019 · J Roeper, M Falk, et al. · Pneumologie · 1
P74.02 Treatment Patterns of EGFR mt+ NSCLC IV pts: Real World Data of the NOWEL Network
2021 · J. Roeper, M. Falk, et al. · Journal of Thoracic Oncology
PDF
Treatment patterns of EGFR mt+ NSCLC IV patients: Real world data of the NOWEL network
2020 · J Roeper, K Wedeken, et al. · Pneumologie
Immuntherapie des metastasierten nichtkleinzelligen Lungenkarzinoms
2019 · Sandra Sackmann, Samuel Ogundele, et al. · Der Pneumologe
Junge Patientin mit Lungenkarzinom: Komplexität der pathologischen Untersuchungen
2019 · S Sackmann, T Tiedje, et al. · Pneumologie
Aspirationspneumonien und nichttuberkulöse Mykobakteriosen als Dauerproblem bei Zustand nach Gastrektomie
2019 · T Tiedje, S Sackmann, et al. · Pneumologie
Risk of not receiving second-line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts
2018 · J. Roeper, M. Falk, et al. · Annals of Oncology
163P The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network
2018 · J. Roeper, M. Netchaeva, et al. · Journal of Thoracic Oncology
PDF
Impact on OS and PFS of 2nd and 3 rd Generation TKI in EGFR mt+ and ALK+ patients: Results of the NOWEL network
2018 · J Roeper, M Netchaeva, et al. · Pneumologie
Zielgerichtete Systemtherapie des metastasierten NSCLC: RET-Mutation als Resistenzmechanismus gegenüber ALK-Inhibitor
2018 · S Sackmann, H Golke, et al. · Pneumologie
P3.01-038 Impact on OS and PFS of 2nd and 3rd Generation TKI in EGFR Mt+ and ALK+ Patients: Results of the NOWEL Network
2017 · J. Roeper, M. Netchaeva, et al. · Journal of Thoracic Oncology
Mann (geb. 1962) mit NSCLC IV-Adenokarzinom (EGFR-Mutation positiv): seit 7 Jahren Therapie mit u.a. Gefitinib, Bevacizumab und aktuell Osimertinib – und die Erfolgsgeschichte geht weiter …
2017 · H Haars, S Sackmann, et al. · Pneumologie
Management einer Tuberkulose nach DRESS-Syndrom auf Therapie mit Erstrang-Antituberkulotika – eine Kasuistik
2017 · T Tiedje, H Berger, et al. · Pneumologie
Works count: 31
Citation count: 58
H-index: 5
I10-index: 3
Year
Topic
Type